Letter to the Editor Regarding Erythropoietin-Stimulating Agents Resistance in Haemodialysis-Treated Patients: Time for a Treatment Shift?

The incidence of chronic kidney disease (CKD) is increasing worldwide, and the current prevalence rate is about 8% –16% [1]. More than half a million adults in the USA have CKD requiring dialysis treatment and>90% of patients on dialysis have anaemia, leading to increased morbidity and mortality. Traditional treatment for renal anaemia includes iron agents and erythropoiesis-stimulating agents (ESAs). Responsiveness to ESAs is associated with increased cardiovascular disease (CVD) risk and mortality in patients undergoing haemodialysis (HD).
Source: Heart, Lung and Circulation - Category: Cardiology Authors: Tags: Letter to the Editor Source Type: research